Navigation Links
Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
Date:12/11/2008

sarcoma 9* SD (tumour resection after cycle 4) ------------------------------------------------------------------------- Chordoma 6* SD ------------------------------------------------------------------------- Unspecified Spindle Cell 6* SD ------------------------------------------------------------------------- * patients still on study

"We are very pleased to have met the statistical endpoint in our first U.S. Phase 2 study, particularly in such a difficult-to-treat form of cancer," said Dr. Brad Thompson, President and CEO of Oncolytics. "The interim data indicate that REOLYSIN(R) is active in various types of metastatic sarcoma, and that late-stage clinical trials are justified."

Sarcomas are malignant tumors growing from connective tissues, such as cartilage, fat, muscle, or bone. According to the American Cancer Society, only 16.3% of patients with distant spread of sarcoma live longer than five years. There is an unmet medical need for effective treatments for patients with this type of disease.

Clinical Trial Design

The trial (REO 014) is a Phase 2, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN(R) in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN(R) is delivered intravenously to patients at a dose of 3x10(10) TCID(50) for five consecutive days, every 28 days. Up to 52 patients will be enrolled in the study.

Eligible patients must have a bone or soft tissue sarcoma metastatic to the lung deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Local veterinarian, Dr. ... Hospital are seeking candidates to participate in an investigational ... The ultimate goal of this study is to ... into one or two arthritically affected joints can help ... , Candidates for the current investigational study must be ...
(Date:8/29/2014)... Due to a misstatement posted by the Family Resource ... Center, LLC ( ASCTC ) was reported as an entity ... benefit ALS patients. Because of ASCTC's exclusive focus on ... therapeutic applications, FRC listed ASCTC as one of several alternatives ... not to support research that requires the death of human ...
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... Nevada City, CA (PRWEB) August 28, 2014 ... and sanitation products for the food processing industry, is ... conducting a side-by side comparison of the E2 soap ... Q E2 Sanitizing Foam Soap . Hand hygiene ... pathogens in the food processing environment. Six key criteria ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... ATLANTA, May 1 CryoLife, Inc., (NYSE: ... company, announced today,that Harvey Morgan has been elected ... Morgan is a Managing Director at Bentley,Associates L.P., ... more than 35 years of investment banking experience ...
... accelerating market penetration and revenue growth, SCOTTSDALE, ... technology company that markets the Provant(R) Wound Therapy,System, ... as Vice,President of Marketing. Most recently Mr. Robey ... Inc (KCI) for the V.A.C.(R) Therapy,brand, during the ...
... SEATTLE, May 1 Therapies under development to ... growth factor,(IGF-1) to activate its target receptor could ... gene -- p53 -- is already,compromised, according to ... Center., IGF-1 is a polypeptide hormone that ...
Cached Biology Technology:Harvey Morgan Joins CryoLife Board of Directors 2Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing 2New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor 2New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor 3
(Date:8/29/2014)... has been known about what genetic changes transform wild ... one of whom is a University of Montana assistant ... controlling the development of the brain and the nervous ... was published Aug. 28 in Science and ... at http://www.sciencemag.org/ ., The domestication of animals and ...
(Date:8/29/2014)... in German . ... natural nitrogen cycle on Earth and in biological wastewater ... to depend on nitrite as their source of energy. ... a microbiologist at the University of Vienna, has now ... alternative source of energy. The oxidation of hydrogen with ...
(Date:8/29/2014)... Bend them, stretch them, twist them, fold them: modern ... extraordinary technological potential, whether as artificial skin or electronic ... use remains a challenge but a new way of ... could be a game-changer. , Previous success in ... on the use of precious gold and silver nanowires. ...
Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Copper shines as flexible conductor 2
... to treat bacterial infections causes a continual and vicious ... and spread of resistant strains, forcing the use of ... what if it doesn,t have to be that way? ... Biochemistry and Molecular Biology,s annual meeting, titled "Driving backwards ...
... We all know that eating a calcium-rich diet is ... concept is clearly on display in any elementary school ... with celebrity icons encouraging children to make sure they ... urging school-aged children to pay attention to their dairy ...
... genes out of action allows researchers to learn what genes ... Utah biologists pioneered the field. Mario Capecchi won a Nobel ... to cripple fruit fly genes. Now, biologist Erik Jorgensen and ... nematode worms. "We developed a method that allows us ...
Cached Biology News:Putting bacterial antibiotic resistance into reverse 2Study suggests a much earlier onset for bone problems 2Study suggests a much earlier onset for bone problems 3Worm genes KO'd 2Worm genes KO'd 3Worm genes KO'd 4Worm genes KO'd 5